# EDGAR Filing Document

**Accession Number:** 0001849296
**File Stem:** 0001493152-26-026927
**Filing Date:** 2026-6
**Character Count:** 5084
**Document Hash:** 74570ca342d6193b557605111f74b15c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-026927.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001493152-26-026927

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Denoyer Bernard
- **CENTRAL INDEX KEY:** 0001397636

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41386
- **FILM NUMBER:** 261058421

**MAIL ADDRESS:**
- **STREET 1:** C/O CALLISTO PHARMACEUTICALS, INC.
- **STREET 2:** 420 LEXINGTON AVENUE, SUITE 1609
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OKYO Pharma Ltd
- **CENTRAL INDEX KEY:** 0001849296
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**BUSINESS ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA
- **BUSINESS PHONE:** 44 (0) 207 495 2379

**MAIL ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Denoyer Bernard<br><sub>(Last) (First) (Middle)</sub><br>C/O OKYO PHARMA LTD,<br>14-15 CONDUIT STREET<br><sub>(Street)</sub><br>LONDON, UNITED KINGDOM W1S 2XJ<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>OKYO Pharma Ltd [ OKYO ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Options | 2024-03-14 | 2033-03-14 | common stock | 770 | $2.13 | D |  |
| Options | 2025-03-14 | 2033-03-14 | common stock | 769 | $2.13 | D |  |
| Options | 2026-03-14 | 2033-03-14 | common stock | 769 | $2.13 | D |  |
| Options | 2027-03-14 | 2033-03-14 | common stock | 769 | $2.13 | D |  |
| Options | 2025-03-13 | 2034-03-13 | common stock | 3333 | $1.46 | D |  |
| Options | 2026-03-13 | 2034-03-13 | common stock | 3334 | $1.46 | D |  |
| Options | 2027-03-13 | 2034-03-13 | common stock | 3333 | $1.46 | D |  |
| Options | 2026-01-29 | 2035-01-29 | common stock | 1204 | $1.6 | D |  |
| Options | 2027-01-29 | 2035-01-29 | common stock | 1204 | $1.6 | D |  |
| Options | 2028-01-29 | 2035-01-29 | common stock | 1205 | $1.6 | D |  |
| Options | 2026-03-25 | 2035-03-25 | common stock | 3750 | $1.5 | D |  |
| Options | 2027-03-25 | 2035-03-25 | common stock | 3750 | $1.5 | D |  |
| Options | 2028-03-25 | 2035-03-25 | common stock | 3750 | $1.5 | D |  |
| Options | 2029-03-25 | 2035-03-25 | common stock | 3750 | $1.5 | D |  |

---

**Signature:** /s/ Bernard Denoyer  
**Date:** 2026-06-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**